Drug-food interactions: Risk assessment and clinical management strategies to enhance medication safety

Abstract

Drug-food interactions can change medicine exposure and clinical response. They can cause toxicity or treatment failure. Medication safety needs structured risk assessment and practical management steps. This paper reviews mechanisms and real, publicly available evidence. We used open full texts and regulator materials. We searched PubMed Central, DailyMed labels, and national safety alerts. We included crossover trials, prospective cohorts, and controlled laboratory digestion models. We extracted effect size, risk factors, and clinical advice statements. A crossover trial found grapefruit juice increased simvastatin exposure. Simvastatin AUC rose 3.6-fold in ten volunteers. Apple juice reduced fexofenadine exposure in a volume-dependent pattern. AUC ratios fell to 0.59 with 300 mL and 0.39 with 600 mL. A prospective cohort linked vitamin K intake patterns to poor warfarin control. Moderate vitamin K intake had the lowest predicted risk of low PTTR. Food increases rivaroxaban exposure at 15-20 mg doses. Product information reports a mean AUC rise of 39% with food. Tea consumed near levothyroxine dosing linked to higher TSH. Avoiding tea and coffee near dosing reduced TSH after three months. We propose a practical risk matrix. It uses interaction magnitude, drug vulnerability, and monitoring ease. We then give clinical strategies for prescribing, counselling, and follow-up. The approach supports safer therapy in community and hospital settings.